Role of TGFB1 polymorphism in the development of metastatic brain tumors in non-small cell lung cancer patients

Genetics and Molecular Research

Volumn 14, Issue 2, 2015, Pages 3545-3550

  Wang, H B ^a   Song, W G ^a   Liu, H Q ^a   Fang, F ^a   Xiao, Y ^a  

^a Department of Radiotherapy and Chemotherapy Tangshan Gongren Hospital ^*  (China)

Author keywords

Brain metastasis; Non small cell lung cancer; Polymorphism; TGFB1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TGFB1 GENE; AGED; BRAIN TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RISK FACTOR; SECONDARY;

ADULT; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84928118889     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.April.17.3     Document Type: Article

References (21)

1. Bovi JA and White J (2012). Radiation therapy in the prevention of brain metastases. Curr. Oncol. Rep. 14: 55-62.
2. Derynck R, Akhurst RJ and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129.
3. Finger EC, Turley RS, Dong M, How T, et al. (2008). TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29: 528-535.
4. Gaspar LE, Scott C, Murray K and Curran W (2000). Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47: 1001-1006.
5. Gaur P, Mittal M, Mohanti BK and Das SN (2011). Functional genetic variants of TGF-β1 and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Oncol. 47: 1117-1121.
6. Gore EM, Bae K, Wong SJ, Sun A, et al. (2011). Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J. Clin. Oncol. 29: 272-278.
7. Javelaud D, Alexaki VI and Mauviel A (2008). Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 21: 123-132.
8. Kang Y, Prentice MA, Mariano JM, Davarya S, et al. (2000). Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis. Exp. Lung Res. 26: 685-707.
9. Li Q, Wu H, Chen B, Hu G, et al. (2012). SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer. PLoS One 7: e51713.
10. Massagué J (1998). TGF-beta signal transduction. Annu. Rev. Biochem. 67: 753-791.
11. Massagué J (2008). TGFbeta in cancer. Cell 134: 215-230.
12. Massagué J and Gomis RR (2006). The logic of TGFbeta signaling. FEBS Lett. 580: 2811-2820.
13. Nathoo N, Chahlavi A, Barnett GH and Toms SA (2005). Pathobiology of brain metastases. J. Clin. Pathol. 58: 237-242.
14. Roberts AB (1999). TGF-beta signaling from receptors to the nucleus. Microbes Infect. 1: 1265-1273.
15. Saunier EF and Akhurst RJ (2006). TGF beta inhibition for cancer therapy. Curr. Cancer Drug Targets 6: 565-578.
16. Slattery ML, Lundgreen A, Herrick JS, Wolff RK, et al. (2011). Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer 117: 4175-4183.
17. Subramanian A, Harris A, Piggott K, Shieff C, et al. (2002). Metastasis to and from the central nervous system - the ‘relatively protected site’. Lancet Oncol. 3: 498-507.
18. Tsuchida K, Sunada Y, Noji S, Murakami T, et al. (2006). Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev. Med. Chem. 6: 1255-1261.
19. Wakefield LM and Roberts AB (2002). TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12: 22-29.
20. Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, et al. (2014). Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor b1 signaling in metastatic breast cancers. Breast Cancer Res. 16: R24.
21. Yuan X, Wei Q, Komaki R, Liu Z, et al. (2013). TGFb1 polymorphisms predict distant metastasis-free survival in patients with inoperable non-small-cell lung cancer after definitive radiotherapy. PLoS One 8: e65659.